Longitudinal changes in type 2 and Aspergillus-specific biomarkers during omalizumab therapy for allergic bronchopulmonary aspergillosis: a 36-week study in Chinese patients
Allergic bronchopulmonary aspergillosis (ABPA) is a severe type 2 inflammatory airway disease caused by hypersensitivity to Aspergillus fumigatus . Although omalizumab has been used as an adjunctive therapy for ABPA, longitudinal changes in type 2 inflammatory and Aspergillus -specific biomarkers during treat...